Skip to content

Long-term Bilateral Theta Burst Stimulation for the Treatment of Major Depression

Status
Completed
Phases
Phase 2Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01153139
Acronym
TheBuS_D
Enrollment
32
Registered
2010-06-29
Start date
2010-04-30
Completion date
2013-07-31
Last updated
2013-07-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Major Depression

Keywords

Transcranial Magnetic Stimulation, Depression, Theta Burst Stimulation

Brief summary

Repetitive transcranial magnetic stimulation has been shown to be moderately effective in the treatment of major depression. Theta burst stimulation (TBS) is a new form of rTMS that may exert larger effects. This sham-controlled study examines the effectivity of daily bilateral TBS to the dorsolateral frontal cortex over 6 weeks in 2x16 patients with major depression add on to the local standard of a combined pharmacological/psychotherapeutical treatment.

Interventions

DEVICERepetitive Transcranial Magnetic Stimulation (Theta Burst Stimulation, TBS)

intermittent TBS (iTBS) to the left DLPFC (600 stimuli, 80% resting motor threshold) continuous TBS (cTBS) to the right DLPFC (600 stimuli, 80% resting motor threshold)

Sponsors

University Hospital Tuebingen
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Caregiver, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No

Inclusion criteria

* major Depression * informed consent

Exclusion criteria

* seizures in medical history * metallic implants * deep brain stimulation * cardiac pacemaker * brain trauma * psychotic symptoms * substance abuse * pregnancy * Benzodiazepines other than Lorazepam \>1mg/d

Design outcomes

Primary

MeasureTime frame
Number of responders (response = decrease of the Montgomery-Åsberg Depression Rating Scale for at least 50%)after the end of treatment (week 6)

Secondary

MeasureTime frame
Change of the Hamilton rating scale for depression (HAMD 17)baseline, after the end of treatment (week 6)
Change of the Beck Depression Inventory (BDI)baseline, after the end of treatment (week 6)
Change of the Montgomery-Asberg rating scale for depression (MADRS) scorebaseline, after the end of treatment (week 6)

Countries

Germany

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026